Specifically, high levels of AKR1B10 significantly impact the overall survival (OS) and disease-specific survival (DSS) of HCC patients, while progression-free survival (PFS) and disease-free interval (DFI) are not affected by AKR1B10 expression (Fig. 4b–e). This evidence concerns the gene AKR1B10 and hepatocellular carcinoma.